Printer Friendly

EMMAC acquires 100% of Terra Verde with the oldest cannabis cultivation licence in Portugal.

M2 PHARMA-July 16, 2019-EMMAC acquires 100% of Terra Verde with the oldest cannabis cultivation licence in Portugal

(C)2019 M2 COMMUNICATIONS

European medical cannabis company EMMAC Life Sciences Ltd revealed on Monday the completion of the acquisition of 100% of Terra Verde LDA.

Upon closing, the acquisition establishes EMMAC as the largest vertically integrated cannabis company in Europe, with operations in eight territories and licensed distribution channels for medical cannabis in Europe's largest medical cannabis markets, namely Germany, Italy and the UK.

In conjunction with the acquisition, EMMAC will begin to invest significantly in Terra Verde's facilities, including the construction of a GMP-certified facility for storage, processing and manufacturing at the Portuguese site that will serve both the domestic and the international markets.

This acquisition is EMMAC's largest acquisition to date and completes the full integration of its supply chain, which comprises of GACP cultivation, extraction and manufacturing in accordance with EU Good Manufacturing Practices (GMP) and licensed distribution channels for medical cannabis in the UK, Germany and Italy.

The Portuguese genetics and cultivation company Terra Verde was founded by David Yarkoni, a world-renowned breeder and geneticist who has pioneered plant-based research and production for more than 30 years. In 2014, Terra Verde acquired Portugal's first, and Europe's second, active cultivation license, which allows for eight hectares of greenhouse and outdoors cannabis cultivation. Its current crop of high-grade medical cannabis is due for harvest in 30 days.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jul 16, 2019
Words:248
Previous Article:Propanc Biopharma provides update on PRP clinical trial application and reverse common stock split.
Next Article:RaySearch and Vision RT to work together on technology development projects under strategic partnership.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters